pdf   xlsx method abbreviations

lung cancer : non small cell (NSCLC), durvalumab plus osimertinib , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 2.60 [0.39, 17.16]< 10%1 study (1/-)16.2 %NAnot evaluable crucial-
progression or deaths (PFS) 1.10 [0.22, 5.61]< 10%1 study (1/-)45.5 %NAnot evaluable important-
objective responses (ORR) 0.45 [0.08, 2.40]> 10%1 study (1/-)17.6 %NAnot evaluable non important-

safety endpoints 00

AE (any grade) 1.43 [0.03, 77.69]< 10%1 study (1/-)43.1 %NAnot evaluable non important-
AE (grade 3-4) 12.38 [1.29, 118.34]< 10%1 study (1/-)1.5 %NAnot evaluable non important-
AE leading to death (grade 5) 0.70 [0.01, 37.74]< 10%1 study (1/-)56.9 %NAnot evaluable non important-
SAE (any grade) 1.64 [0.32, 8.45]< 10%1 study (1/-)27.9 %NAnot evaluable non important-
STRAE (any grade) 0.33 [0.01, 10.81]< 10%1 study (1/-)72.9 %NAnot evaluable non important-
TRAE (any grade) 2.33 [0.41, 13.17]< 10%1 study (1/-)17.0 %NAnot evaluable non important-
TRAE (grade 3-4) 7.08 [0.34, 148.71]< 10%1 study (1/-)10.7 %NAnot evaluable non important-

AE (grade 3-4) endpoints 00

Arthralgia AE (grade 3-4) 0.70 [0.01, 37.74]< 10%1 study (1/-)56.9 %NAnot evaluable non important-
Back pain AE (grade 3-4) 0.70 [0.01, 37.74]< 10%1 study (1/-)56.9 %NAnot evaluable non important-
Constipation AE (grade 3-4) 0.70 [0.01, 37.74]< 10%1 study (1/-)56.9 %NAnot evaluable non important-
Cough AE (grade 3-4) 0.70 [0.01, 37.74]< 10%1 study (1/-)56.9 %NAnot evaluable non important-
Diarrhoea AE (grade 3-4) 1.44 [0.04, 46.58]< 10%1 study (1/-)42.0 %NAnot evaluable non important-
Dry skin AE (grade 3-4) 0.70 [0.01, 37.74]< 10%1 study (1/-)56.9 %NAnot evaluable non important-
Dyspnoea AE (grade 3-4) 0.70 [0.01, 37.74]< 10%1 study (1/-)56.9 %NAnot evaluable non important-
Nausea AE (grade 3-4) 0.70 [0.01, 37.74]< 10%1 study (1/-)56.9 %NAnot evaluable non important-
Neutropenia AE (grade 3-4) 3.07 [0.13, 74.70]< 10%1 study (1/-)24.9 %NAnot evaluable non important-
Pneumonia AE (grade 3-4) 3.07 [0.13, 74.70]< 10%1 study (1/-)24.9 %NAnot evaluable non important-
Pruritus AE (grade 3-4) 0.70 [0.01, 37.74]< 10%1 study (1/-)56.9 %NAnot evaluable non important-
Rash AE (grade 3-4) 0.70 [0.01, 37.74]< 10%1 study (1/-)56.9 %NAnot evaluable non important-
Stomatitis AE (grade 3-4) 0.70 [0.01, 37.74]< 10%1 study (1/-)56.9 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons